epinephrine in COVID-19

Phase 2

• Conditions: COVID-19, virus identified.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20200506047323N8
• Lead Sponsor: Bandare-abbas University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 May 2021

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 84

Inclusion Criteria

Age between 18 and 80 years
Positive polymerase chain reaction (PCR) test for COVID-19
Hospitalized
Signing informed consent and willingness of study participant to accept randomization to any assigned treatment a

Exclusion Criteria

Contraindications epinephrine including, hemorrhagic CVA, TIA, and acute MI
Heart rate > 100
History of allergy to epinephrine
Pregnancy and breastfeeding

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical symptoms. Timepoint: Before intervention and daily during the study. Method of measurement: Questionnaire.;Oxygen saturation. Timepoint: Before intervention and daily during the study. Method of measurement: Pulse oximeter.;Pulmonary imaging finding. Timepoint: Before intervention and the fifth day of the study. Method of measurement: Computed tomography.

Secondary Outcome Measures

Name	Time	Method
Incidence of serious adverse events. Timepoint: Before intervention and daily during the study. Method of measurement: Questionnaire.